These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 12064317)

  • 1. Delavirdine in rescue regimens.
    TreatmentUpdate; 2002; 14(4):6. PubMed ID: 12064317
    [No Abstract]   [Full Text] [Related]  

  • 2. Delavirdine (Rescriptor).
    Res Initiat Treat Action; 2000 Mar; 6(1):20-1. PubMed ID: 11708180
    [No Abstract]   [Full Text] [Related]  

  • 3. Delavirdine/protease inhibitor interactions.
    Gilden D
    GMHC Treat Issues; 1996 Sep; 10(9):11-2. PubMed ID: 11363839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can delavirdine substitute for ritonavir?
    TreatmentUpdate; 2001; 13(7):8. PubMed ID: 11794866
    [No Abstract]   [Full Text] [Related]  

  • 5. Strategy update: protease-sparing regimens.
    Proj Inf Perspect; 1998 Dec; (26):14-5. PubMed ID: 11366490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks.
    Murphy RL
    Antivir Ther; 1999; 4 Suppl 3():85-7. PubMed ID: 16021877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nevirapine and delavirdine plus protease inhibitors.
    GMHC Treat Issues; 1996 Apr; 10(4):8. PubMed ID: 11363709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The current role of ritonavir-boosted protease inhibitors in the management of HIV infection.
    Wilkins E
    J HIV Ther; 2008 Mar; 13(1):9-18. PubMed ID: 18953268
    [No Abstract]   [Full Text] [Related]  

  • 9. Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infections.
    Tan D; Walmsley S
    Expert Rev Anti Infect Ther; 2007 Feb; 5(1):13-28. PubMed ID: 17266450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients.
    Bénard A; Damond F; Campa P; Peytavin G; Descamps D; Lascoux-Combes C; Taieb A; Simon F; Autran B; Brun-Vézinet F; Chêne G; Matheron S;
    AIDS; 2009 Jun; 23(9):1171-3. PubMed ID: 19349850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
    Delfraissy JF; Flandre P; Delaugerre C; Ghosn J; Horban A; Girard PM; Norton M; Rouzioux C; Taburet AM; Cohen-Codar I; Van PN; Chauvin JP
    AIDS; 2008 Jan; 22(3):385-93. PubMed ID: 18195565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of delavirdine on plasma lipids and lipoproteins in patients receiving antiretroviral therapy.
    Roberts AD; Liappis AP; Chinn C; Parenti DM; Muesing RA; Schuck SZ; Hsia J; Simon GL
    AIDS; 2002 Sep; 16(13):1829-30. PubMed ID: 12218397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Enduringly effective and tolerable initial therapy of HIV. Even after 5 years no resistance].
    MMW Fortschr Med; 2003 Dec; 145(50):60-1. PubMed ID: 14963980
    [No Abstract]   [Full Text] [Related]  

  • 14. 96-week CASTLE data show similar efficacy results.
    AIDS Patient Care STDS; 2008 Nov; 22(11):918. PubMed ID: 19043840
    [No Abstract]   [Full Text] [Related]  

  • 15. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children.
    Sáez-Llorens X; Violari A; Deetz CO; Rode RA; Gomez P; Handelsman E; Pelton S; Ramilo O; Cahn P; Chadwick E; Allen U; Arpadi S; Castrejón MM; Heuser RS; Kempf DJ; Bertz RJ; Hsu AF; Bernstein B; Renz CL; Sun E
    Pediatr Infect Dis J; 2003 Mar; 22(3):216-24. PubMed ID: 12634581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience with the combined use of lopinavir/ritonavir and rifampicin.
    L'homme RF; Nijland HM; Gras L; Aarnoutse RE; van Crevel R; Boeree M; Brinkman K; Prins JM; Juttmann JR; Burger DM
    AIDS; 2009 Apr; 23(7):863-5. PubMed ID: 19352137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. French investigators warn of LPV/TDF/ddI interaction.
    Carter M
    IAPAC Mon; 2003 Dec; 9(12):315. PubMed ID: 15055164
    [No Abstract]   [Full Text] [Related]  

  • 18. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.
    Kempf DJ; King MS; Bernstein B; Cernohous P; Bauer E; Moseley J; Gu K; Hsu A; Brun S; Sun E
    J Infect Dis; 2004 Jan; 189(1):51-60. PubMed ID: 14702153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.
    Raguin G; Chêne G; Morand-Joubert L; Taburet AM; Droz C; Le Tiec C; Clavel F; Girard PM;
    Antivir Ther; 2004 Aug; 9(4):615-25. PubMed ID: 15456093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of evidence for an effect of lopinavir/ritonavir on tenofovir renal clearance.
    Ray AS; Wright MR; Rhodes GR
    Clin Pharmacol Ther; 2008 Dec; 84(6):660; author reply 661. PubMed ID: 18615003
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.